Search clinical trials for: FG-4592

Total 85 results

FibroGen
AstraZeneca

Withdrawn

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia

United States
FibroGen

Completed

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

Anemia in Chronic Kidney Disease

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

Anemia

China
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
FibroGen

Completed

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

Healthy Adult Subjects
FibroGen
Peking University First Hospital; Peking Union Medical College Hospital; First... and other collaborators

Completed

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Anemia in End Stage Renal Disease

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Anemia

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
FibroGen

Completed

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

CKD Anemia in Dialysis Participants

China
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
Astellas Pharma Inc

Completed

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Anemia | Chronic Kidney Disease

United States
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Anemia | Chronic Kidney Disease

United States, Puerto Rico
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Anemia | End Stage Renal Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Spain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
FibroGen

Completed

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Chemotherapy Induced Anemia

China
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Anemia | End Stage Renal Disease | Chronic Kidney Disease

Puerto Rico, United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees)

Anemia | End Stage Renal Disease (ESRD)

Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Russian Federation, Serbia, Spain, United Kingdom, Belgium, France, Georgia, Italy, Portugal, Romania, Slovakia
Guili Wang

Recruiting

Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material PLCL/Fg

Diabetic Foot

China
University of Minnesota

Completed

Health Wearables and College Student Health

Physical Activity | Technology | Intervention | Behavior Change | Young Adults

United States
FibroGen

Terminated

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis

United States
FibroGen

Completed

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus

United States
FibroGen

Terminated

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, China, Australia, Korea, Republic of, Taiwan, Russian Federation, Hong Kong, Argentina, Chile
Oslo University Hospital
University of Oslo

Completed

Impact of Online Patient Feedback (OQ) to Therapist

Drug Abuse | Drug Addiction

Norway
Novindiet Clinic
Tehran University of Medical Sciences; University of Nottingham

Completed

Effects of Moderate Consumption of Lean Fish on Weight Loss

Obesity | Overweight

Iran, Islamic Republic of
Z Optics, Inc.

Not yet recruiting

Evaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optic

Cataract | Presbyopia | Intraocular Lens
FibroGen

Terminated

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

COVID-19

United States
FibroGen

Terminated

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, France, United Kingdom, Korea, Republic of, Lebanon, Denmark, China, Italy, Spain, Serbia, Germany, Netherlands, Czechia, Brazil, Poland, Argentina, Colombia, Dominican Republic, Georgia, Hungary, Ireland, Mexico, Peru, Switzerlan... and more
Cognito Therapeutics, Inc.

Active, not recruiting

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Dementia, Alzheimer Type | Memory Disorders | Memory Impairment | Alzheimer Dementia | Memory Loss | Dementia, Mild | Memory Disorders, Age Related

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Pancreatic Cancer
FibroGen

Completed

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Mersana Therapeutics
IQVIA Biotech

Terminated

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Ovarian Cancer | Nonsmall Cell Lung Cancer

United States
FibroGen

Active, not recruiting

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

Duchenne Muscular Dystrophy

United States, Spain, Canada, Australia, China, Italy, Belgium, France, Netherlands, Austria, United Kingdom
FibroGen

Completed

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer

United States
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) (LELANTOS-1)

Duchenne Muscular Dystrophy

United States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Chronic Graft-versus-host Disease (cGVHD)

United States
FibroGen

Completed

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Diabetes Mellitus | Diabetic Nephropathy

United States
FibroGen

Completed

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis (FGCL-3019-049)

Idiopathic Pulmonary Fibrosis

United States
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Cnoga Medical Ltd.
Carmel Medical Center

Completed

A Comparative Study of the SoftTouch Non-Invasive Finger-Mounted Device

Accuracy of the SofTouch Device Measuring Blood Glucose and Other Parameters

Israel
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

Chronic Graft-versus-Host Disease (cGVHD)

Australia

Search clinical trials for: FG-4592

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations